Radiation therapy in operable and locally advanced pancreatic cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 9, 2010, Pages 1022-1031

  Ko, Andrew H ^a   Crane, Christopher H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemoradiation; Chemotherapy; Locally advanced; Pancreatic cancer; Stereotactic

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; STREPTOZOCIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYBERKNIFE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; DRUG TOLERABILITY; DUODENUM ULCER; FATIGUE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; HUMAN; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENETICS; RADIATION DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOTACTIC BODY RADIATION THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 77958181832     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0074     Document Type: Review

References (50)

1. Hattangadi JA, Hong TS, Yeap BY, et al. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 2009;115:3640-650.
2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
3. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-1026.
4. Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195-200.
5. Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009;35:600-604.
6. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-1813.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
8. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
9. Eppsteiner RW, Csikesz NG, McPhee JT, et al. Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg 2009;249:635-640.
10. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-3510.
11. Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
12. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782.
13. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007;246:734-740.
14. Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008;15:2773-2786.
15. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277.
16. Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract LBA 4504.
17. Neoptolemos J, Büchler M, Stocken DD, et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract LBA 4505.
18. Laethem JLV, Mornex F, Azria D, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203) [abstract]. J Clin Oncol 2009;27(Suppl1):Abstract 4527.
19. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502.
20. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-3495.
21. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846.
22. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156.
23. Laheru D, Yeo C, Biedrzycki B, et al. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3010
24. Picozzi VJ, Abrams RA, Traverso LW, et al. ACOSOG Z05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon [asbtract]. J Clin Oncol 2008;26(Suppl 1): Abtract A-4505.
25. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-195.
26. Kindler H, Friberg G, Stadler W, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 4009.
27. Loehrer P, Powell M, Cardenes H, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4506.
28. Poplin E, Levy D, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201) [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract LBA4004.
29. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paditaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004;27:51-56.
30. Rich T, Myerson R, Harris J, et al. A randomized phase II trial of weekly gemcitabine (G), paclitaxel (P), and external irradiation followed by the farnesyl transferase inhibitor R115777 (NSC#702818) for locally advanced pancreatic cancer (RTOG 0020) [abstract]. Presented at the 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, California. Abstract A-121.
31. Crane CH, Winter K, Regine WF, et al. Phase II Study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009;27:4096-4102.
32. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-1599.
33. Crane C, Varadhachary G, Javle M, et al. Multi-institutional phase II trial of induction cetuximab, gemcitabine, and oxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, for locally advanced pancreatic adenocarcinoma (LAPC) [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 132.
34. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-331.
35. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145-1151.
36. Ko AH, Quivey JM, Venook AP, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:809-816.
37. Ben-Josef E, Griffith K, Francis IR, et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4602.
38. Tamm EP, Loyer EM, Faria S, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 2006;31:568-574.
39. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017-1021.
40. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:320-323.
41. Schellenberg D, Goodman K, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008;72:678-686.
42. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009;115:665-672.
43. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005;76:48-53.
44. Moertel CG, Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867.
45. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979;189:205-208.
46. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710.
47. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378.
48. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-755.
49. Kindler HL, Niedzwiecki D, Hollis DR, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 [abstract]. J Clin Oncol 2007;26(Suppl 1):Abstract A108.
50. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008;19:86-91.